NCT00235300已完成2 期
An Open-Label Prospective, Randomized, Multicenter Phase II Comparative Trial of Thymoglobulin® Versus Simulect® for the Prevention of Delayed Graft Function and Acute Allograft Rejection in Renal Allograft Recipients
Genzyme, a Sanofi Company28 个研究点 分布在 5 个国家目标入组 240 人开始时间: 2000年5月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 240
- 试验地点
- 28
- 主要终点
- Freedom from acute rejection, kidney transplant loss, delayed kidney transplant function and death at 6 months after transplant.
研究概览
简要总结
A multicenter clinical study comparing event-free survival at 6 months after transplant between Thymoglobulin-treated and Simulect-treated adult kidney transplant patients. Patients received Thymoglobulin or Simulect from Day 0 through Day 4. Day 0 was considered the day of the transplant procedure.
Subjects meeting all inclusion and exclusion criteria were eligible to participate in this study. The treatment assignment was random and not chosen by the subject or their physician.
Subjects were monitored during treatment with Thymoglobulin and during the transplant hospitalization. Additional subject monitoring occurred up to 12 months after transplant.
278 study subjects were enrolled at 28 transplant centers in the United States and Europe.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient greater than or equal to 18 years old.
- •Patient is classified as "high risk" for acute allograft rejection of DGF. Must have had at least 1 donor or 1 recipient variable for high risk.
- •Patient will be a recipient of a solitary cadaveric renal allograft.
- •Women of childbearing potential must have had a negative pregnancy test (serum or urine).
- •Man or woman agrees to practice medically acceptable contraception (i.e. barrier or pharmacologic) for a minimum of 3 months following study drug administration. In addition, women were recommended to practice contraception for 1 year following transplantation, or per local standard.
- •Patient agrees to participate in the study and sign an informed consent.
- •Patient has no known contraindication to the administration of rabbit anti-thymocyte globulin or basiliximab. Patient has no history of hypersensitivity to basiliximab.
- •Patient is dialysis-dependent at the time immediately prior to transplantation.
排除标准
- •Patient has received an investigational medication within the past 30 days.
- •Patient has a history of malignancy within 2 years, with the exception of adequately treated localized squamous basal cell carcinoma of the skin without evidence of recurrence.
- •Patient is currently abusing drugs or alcohol.
- •Patient is known or suspected to have an active infection or be seropositive for hepatitis B surface antigen (HBsAg), hepatitis C (HCV), or human immunodeficiency virus (HIV).
- •Patient is a multiple organ transplant recipient.
- •Patient is on any type of immunosuppression (i.e. prior transplant recipient still on immunosuppression, or patient is receiving systemic steroids for any medical condition).
- •Patient, who, in the opinion of the investigator, has significant medical or psychosocial problems or unstable disease states which would preclude enrollment. Examples of significant medical problems include, but are not limited to, morbid obesity or severe cardiac disease.
- •Kidneys that are to be implanted en bloc or from donors less than 6 years old.
- •Kidneys from donors that are known or suspected to have an active infection with or be seropositive for HBsAg, hepatitis B core antibody (HBcAb), HCV, or HIV.
- •Kidneys from donors that have received investigational therapies designed to reduce the impact of ischemia reperfusion, DGF, or other donor-related immune events.
- •Donor kidney is preserved by cold storage (with or without machine preservation) for less than 16 hours, with the exception of kidneys from non-heart-beating donors or kidneys from donors greater than 50 years old or donors with a SCr above 2.5mg/dL.
研究组 & 干预措施
1 Control
Active Comparator
Simulect (basiliximab)
干预措施: Simulect (basliximab) (Drug)
2
Experimental
Thymoglobulin (anti-thymocyte globulin (rabbit))
干预措施: Thymoglobulin [Anti-thymocyte Globulin (rabbit)] (Biological)
结局指标
主要结局
Freedom from acute rejection, kidney transplant loss, delayed kidney transplant function and death at 6 months after transplant.
时间窗: 6 months
次要结局
- 12-mo. safety & efficacy assessments including side effects and overall kidney transplant function.(12 months)
研究者
研究点 (28)
Loading locations...
相似试验
已完成
3 期
Study Comparing Cyclosporin Dose Reduction With Cyclosporin Elimination in Kidney Transplant Recipients Taking SirolimusKidney DiseaseNCT00248313Wyeth is now a wholly owned subsidiary of Pfizer470
已完成
3 期
Study Evaluating Sirolimus and Cyclosporine in Kidney Transplant RecipientsRenal TransplantationNCT00428064Wyeth is now a wholly owned subsidiary of Pfizer408
已完成
不适用
Randomized Study of Organ Care System Cardiac for Preservation of Donated Hearts for Eventual TransplantationHeart FailureNCT00855712TransMedics128
已完成
2 期
Pharmacokinetics of LCP-Tacro in Stable Liver Transplant PatientsLiver FailureNCT00608244Veloxis Pharmaceuticals59
尚未招募
不适用
the Efficacy and Safety of Total Myeloid Irradiation (TMI) in the Treatment of Adult Acute Lymphoblastic LeukemiaAcute Lymphoblastic LeukemiaNCT06461091Institute of Hematology & Blood Diseases Hospital, China20